Drug
LOXO-260
LOXO-260 is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph phase_1
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Other(1)
Detailed Status
Active, not recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 11 (100.0%)
Trials by Status
active_not_recruiting150%
unknown150%
Recent Activity
1 active trials
Showing 2 of 2
active_not_recruitingphase_1
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
NCT05241834
unknown
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
NCT05225259
Clinical Trials (2)
Showing 2 of 2 trials
NCT05241834Phase 1
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
NCT05225259
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2